Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors

A compound of the formula:

• wherein:
• R1 is hydrogen, alkyl, halogen, aryl, or heteroaryl;
• R2, R3, R5, and R6 are, independently, hydrogen, hydroxy, lower alkyl, alkoxy, or halogen;
• R4 is alkyl;
• R7 is hydrogen, —(C═O)R16, —S(O)2R17, —S(O)2N(R18)(R19), or D-glucuronidate;
• R16 is alkyl, aralkyl or aryl;
• R17 is alkyl, aryl, heteroaryl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl;
• and
• R18 and R19 are, independently, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, monofluoroalkyl, perfluoroalkyl, aryl, arylalkyl, cycloalkenyl, heteroaryl, heteroarylalkyl, hydroxy-(C2-C6)alkyl, alkoxyalkyl, alkylthioalkyl, carbonyl, acyl, alkoxycarbonyl, —C(O)NH2, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminoalkyl, or dialkylaminoalkyl;
• or R18 and R19 are taken together with the nitrogen atom to which they are attached to form a saturated, unsaturated or partially saturated C4-C6 carbon ring.